Middletown, DE -- (SBWIRE) -- 10/04/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: TiVo Inc.(NASDAQ:TIVO), Arca Biopharma Inc(NASDAQ:ABIO), Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN), MannKind Corporation(NASDAQ:MNKD)
TiVo Inc.(NASDAQ:TIVO) gained volume of 3.53 million shares and the average volume of the stock remained 2.93 million shares. The 52 week range of the stock remained $9.63 - $14.10 and the day range was $12.27 - $12.67.The stock opened the session at $12.50, and closed the session at $12.42. The stock showed a negative performance of -0.48% in previous trading session. TiVo Inc. (TiVo) a developer and provider of software and technology that enables the search, navigation, and access of content across sources, including linear television, on-demand television, and broadband video. TiVo's technology for enabling the TiVo service includes the TiVo service client software platform, the TiVo service infrastructure, and TiVo-enabled hardware designs.
Has TIVO Found The Bottom and Ready To Move Up? Find Out Here
In previous session, Arca Biopharma Inc(NASDAQ:ABIO) traded 3.53 million shares and the average volume of the stock remained 649,433.00 shares. The 52 week range of the stock remained $1.13 - $5.93. The stock was a bear and dropped -2.97%, while its closing price stayed at $1.60. The market capitalization of the stock remained 17.52 million. The half-yearly trend of the stock remained negative -26.94%. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF).
Has ABIO Found The Bottom And Ready To Gain Momentum? Find Out Here
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) volume of the stock was 3.47 million shares in the most recent session and the average volume remained 3.13 million shares. The stock plunged -3.47% and finished the prior session at the closing price of $2.78. The stock traded 3.47 million shares in its previous trading session and its average volume remained 3.13 million shares. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
Why Should Investors Buy ACHN After the Recent Fall? Just Go Here and Find Out
MannKind Corporation(NASDAQ:MNKD) traded with volume of 3.47 million shares and the average volume of the stock remained 5.42 million shares. The stock decreased -2.43% and finished the trading at $5.61. The market capitalization of the stock remained 1.69 billion. The beta of the stock remained 1.63. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.
Will MNKD Get Buyers Even After The Recent Rally? Find Out Here
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)